ANVS logo.jpg
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
11 nov. 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
22 oct. 2024 07h57 HE | ZyVersa Therapeutics
Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.
ANVS logo.jpg
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
03 oct. 2024 08h30 HE | Annovis Bio, Inc.
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer’s Treatment: Innovative...
ANVS logo.jpg
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
30 sept. 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
ANVS logo.jpg
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for...
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
04 sept. 2024 07h46 HE | ANEW MEDICAL, INC.
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
harnesstx-logo.png
Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director
04 sept. 2024 03h00 HE | Harness Therapeutics
Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing on translational medicine and clinical development approaches for one of the...
logo.jpg
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
28 août 2024 09h00 HE | AC Immune SA
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s...
ANEW MEDICAL, INC. Appoints New CFO
19 août 2024 05h00 HE | ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Appoints New CFO
ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases
15 août 2024 05h00 HE | ANEW MEDICAL, INC.
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for...